In summary, these results illustrate that trametinib can inhibit the size of the glioblastoma xenograft and expression of Ki67, ERK and PKM2 in vivo—which achieve the purpose of treating glioma through the PKM2/c-myc axis. This evidence concerns the gene MYC and central nervous system cancer.